Japan Panel OKs iPS Cell Trial for Heart Disease Treatment
Newsfrom JapanSociety Lifestyle Politics
Tokyo, May 16 (Jiji Press)--A Japanese health ministry panel conditionally approved Wednesday the world's first clinical trial for transplants using induced pluripotent stem, or iPS, cells for heart disease treatment.
The regenerative medicine screening panel approved the trial planned by Osaka University depending on the meeting of conditions such as making explanatory documents for patients easier to understand.
The health minister will shortly give official approval to the plan to transplant sheets of heart muscle cells produced from donor iPS cells to severe heart disease patients.
Osaka University will conduct the first of the transplants by the end of March next year at the earliest to investigate the treatment's safety and effectiveness.
The clinical trial plan was submitted to the health ministry in March by a research group led by Osaka University Prof. Yoshiki Sawa, who specializes in cardiovascular surgery.
[Copyright The Jiji Press, Ltd.]